Merck’s Molnupiravir Open License With Medicines Patent Pool May Be Model

Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?

Molnupiravir
Merck licenses its COVID-19 drug molnupiravir to the Medicines Patent Pool • Source: Alamy

Merck & Co., Inc.’s licensing agreement with the Medicines Patent Pool to provide global access to its investigational COVID-19 therapeutic molnupiravir is being praised by industry critics for its transparency and breadth. They view it as a model for future licensing of COVID products.

Merck and the United Nations-backed Medicines Patent Pool (MPP) announced the signing of the voluntary licensing agreement on 27 October,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet